Current Edition


AZ to transfer certain drug rights to Covis Pharma for $270m

AstraZeneca has announced it will transfer global rights to Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group in a $270m ...
Continue Reading →
Volume 13 Issue 3

New DPI Data Insights Shaping Future of Global Healthcare Needs

Innovative inhalation therapies and drug delivery are legacies of the COVID-19 pandemic, as pharma and biopharma formulators address growing demands for new healthca...
Continue Reading →